/PRNewswire/ The inaugural ZAODX World Conference on Early Detection of Cancer ("the Conference") was successfully held at the Chimelong International.
02.06.2022 - BEIJING, June 02, 2022 (GLOBE NEWSWIRE) - Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer .
30.11.2021 - Collaboration highlights the value of MRD solid tumor data generated by Genetron’s Mutation Capsule platform, and further accelerates product developmentBEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) - Genetron Holdings Limited (“Genetron Health” or the . Seite 1
Press release content from Business Wire. The AP news staff was not involved in its creation.
Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar
April 1, 2021 GMT
Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH) sponsored a
Science /AAAS Webinar, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”, which launched today.
During the panel discussion, Genetron Health’s Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled “Profiling cfDNA-based Biomarkers for the Early Detection of Cancer”. In his presentation, Dr. Jiao highlighted the importance of early detection as the most effective method to prevent deaths from cancer.